Results 91 to 100 of about 33,638 (296)
Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. [PDF]
, 2018 Ataxia-telangiectasia confers a significant increase in the development of several cancer types, most commonly leukemia and lymphoma. However, as the natural history for these patients is evolving and their lifespan is increasing, there is the potential ...
Bateni, Cyrus P +5 more
core
JEADV Clinical Practice, EarlyView.ABSTRACT Background Pruritus is a symptom frequently associated with systemic diseases, particularly hematological disorders. Objectives The aim of this study was to evaluate the association of pruritus with morbidity in myeloproliferative neoplasms (MPN).
J. Saucereau +4 more
wiley +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2014 Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce +3 more
doaj +1 more source
Single-cell analysis based dissection of clonality in myelofibrosis
Nature Communications, 2020 Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas +21 more
doaj +1 more source
Rheumatology &Autoimmunity, EarlyView.This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu +8 more
wiley +1 more source
Primary autoimmune myelofibrosis: a report of three cases and review of the literature
Turkish Journal of Hematology, 2009 Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj
JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management
United European Gastroenterology Journal, EarlyView.ABSTRACT JAK inhibitors are pivotal in treating immune‐mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double ...
Luisa Bertin, Edoardo Vincenzo Savarino
wiley +1 more source
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
British Journal of Haematology, EarlyView.Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan +2 more
wiley +1 more source
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Haematologica, 2016 Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of ...
Abdallah Abou Zahr +7 more
doaj +1 more source